HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA
|
disease |
|
Disease or Syndrome
|
2
|
4
|
0.100 |
None |
|
0 |
4
|
|
|
HYPOGONADOTROPIC HYPOGONADISM 21 WITH ANOSMIA, SUSCEPTIBILITY TO
|
phenotype |
|
Finding
|
2
|
3
|
0.100 |
None |
|
0 |
3
|
|
|
Antiphospholipid antibodies measurement
|
phenotype |
|
Laboratory Procedure
|
6
|
8
|
0.100 |
None |
1.000 |
1 |
1
|
2016 |
2016 |
Thyroid associated orbitopathy
|
disease |
|
Disease or Syndrome
|
7
|
4
|
0.010 |
None |
1.000 |
1 |
1
|
2016 |
2016 |
Interleukin 10 Measurement
|
phenotype |
|
Laboratory Procedure
|
14
|
24
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |
Kabuki make-up syndrome
|
disease |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Otorhinolaryngologic Diseases; Hemic and Lymphatic Diseases
|
Congenital Abnormality
|
37
|
253
|
0.020 |
None |
1.000 |
2 |
|
2007 |
2018 |
Depressed bipolar I disorder
|
disease |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
37
|
59
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Corneal Topography
|
phenotype |
|
Diagnostic Procedure
|
39
|
98
|
0.100 |
None |
1.000 |
1 |
1
|
2011 |
2011 |
Stage III Colon Cancer AJCC v7
|
disease |
|
Neoplastic Process
|
42
|
3
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Stage III Colon Cancer AJCC v8
|
disease |
|
Neoplastic Process
|
42
|
3
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Stage III Colon Cancer
|
disease |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
43
|
3
|
0.010 |
None |
1.000 |
1 |
|
2018 |
2018 |
Limb Deformities, Congenital
|
group |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases
|
Congenital Abnormality
|
59
|
4
|
0.010 |
None |
< 0.001 |
1 |
|
2019 |
2019 |
Hip circumference
|
phenotype |
|
Clinical Attribute
|
68
|
116
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |
Duration of sleep
|
phenotype |
|
Finding
|
104
|
203
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Organic Mental Disorders, Substance-Induced
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Prescription Drug Abuse
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Finding
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
121
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance-Related Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
128
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Malignant Fibrous Histiocytoma
|
disease |
Neoplasms
|
Neoplastic Process
|
150
|
3
|
0.010 |
None |
1.000 |
1 |
|
2020 |
2020 |
Substance Dependence
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
156
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Child Development Disorders, Pervasive
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
168
|
379
|
0.100 |
None |
1.000 |
1 |
1
|
2019 |
2019 |
Substance abuse problem
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
185
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug habituation
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
196
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
218
|
16
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Platelet mean volume determination (procedure)
|
phenotype |
|
Laboratory Procedure
|
223
|
371
|
0.100 |
None |
1.000 |
1 |
1
|
2009 |
2009 |